Ann: CEO Investor Presentation, page-17

Mike has focused to educate shareholders about angiography and contrast induced kidney injury and how renal cells in diabetic patients are more prone to injury, instead of giving useful information about the challenges that the company is dealing with, about how the company is looking to expand its portfolio and the market, how the company is going to cut the expenses, how the R$D is spending about $500 quarterly and what the fruit has been.

Mike, at least please let the shareholders know about the next scheduled 1:100 consolidation.